$IRTC

Murphy Patrick Michael sold $884K of IRTC

Murphy Patrick Michael (CBO and CLO) sold 7,093 shares of iRhythm Holdings, Inc. (IRTC) at $124.65 ($0.88M total) on 2026-08-10.

Original reporting
SEC EDGAR · Murphy Patrick Michael
Published Aug 11, 2026, 8:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IRTC
Neutral
medium confidence
Mentioned
$IRTC
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRTCNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details (shares, price, total value, and post-transaction holdings).

02

Market read

Traders may monitor insider activity, but this disclosure alone does not provide new operational or financial information.

03

What to watch

Insider sales are often planned for liquidity or diversification; the article lacks context on total holdings, prior sales cadence, or any concurrent company-specific catalyst.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-11, covering a sale dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for iRhythm Holdings, Inc.

Company-level read

Ticker impact

$IRTCNeutralMedium confidence
Context

IRTC disclosed an officer sale of 7,093 shares on 2026-08-10 for about $884,156, per an SEC Form 4 filing.

Expected impact

Likely limited near-term price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing provides transaction size, price, and role (CBO and CLO) but no accompanying company guidance, operational update, or enforcement/regulatory action.

Market effects

No clear sector read-through from a single insider sale disclosure.

None indicated.

None indicated.

Counterpoint

The absence of a stated 10b5-1 plan could be interpreted as discretionary selling, which some traders may read as caution.

Key entities

  • iRhythm Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Murphy Patrick Michael

    Officer (CBO and CLO) who sold 7,093 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

MedAI 8/10

iRhythm Completes VitalConnect Acquisition

iRhythm Technologies acquired VitalConnect for $287.5M, combining cardiac monitoring technologies. The deal includes $237.5M in cash, 423,334 shares, and $10M in interim capital. VitalConnect's revenue was $65M in 2026. iRhythm aims to boost growth and maintain a 15% EBITDA margin in 2027, with updated guidance expected in Q3 2026 earnings.

$IRTCMedAI 8/10

iRhythm completes acquisition of VitalConnect

iRhythm (IRTC) completed its acquisition of VitalConnect for $237.5M in cash and up to 423,334 shares. The deal includes a $10M working capital funding. VitalConnect's cardiac monitoring platform offers 30-day patient monitoring and 11 physiological parameters. iRhythm expects enhanced revenue growth from 2027, maintaining a 15% adjusted EBITDA margin target. Updated 2026 guidance will be provided in November 2026.

$IRTCMedAI 9/10

Transaction Detail The purchase consideration consisted of $237.5 million in cash, subject to customary adjustments, funded from iRhythm's balance sheet and…

iRhythm Holdings, Inc. (IRTC) filed an SEC Form 8-K — Regulation FD Disclosure. iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care  Combination broadens iRhythm’s cardiac monitoring portfolio, advances its multi-vitals strategy and expands iRhythm’s addressable mark

$IRTCHighAI 9/10

iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care

iRhythm (IRTC) completed its acquisition of VitalConnect, a leader in wearable biosensor and ambulatory cardiac monitoring technology. The $237.5M cash deal, plus up to 423,334 shares, is expected to expand iRhythm's cardiac monitoring portfolio, accelerate growth, and preserve its 15% adjusted EBITDA margin target for 2027. The combined entity aims to serve more patients and customers across various care settings.